Background {#Sec1}
==========

Emergence of carbapenemase-producing *Klebsiella pneumoniae* isolates has become serious problems worldwide \[[@CR1]\]. These isolates produce several carbapenemases belonging to class A, B, and D, including KPCs, NDMs and OXA-48, respectively \[[@CR2]\]. KPC-1 was initially found in a carbapenem-resistant strain *K. pneumoniae* 1534, which was collected in a surveillance during 1996 to 1997 in the United States hospitals \[[@CR3]\]. NDM-1 was initially identified in *K. pneumoniae* and *Escherichia coli* in 2009 in Sweden \[[@CR4]\]. Since then, NDM-1-producing *Enterobacteriaceae* have been reported worldwide \[[@CR5]\]. OXA-48 was first identified in *K. pneumoniae* 11,978, which was isolated in 2001 in Turkey \[[@CR6]\].

*K. pneumoniae* producing 16S rRNA methylase genes responsible for an extremely high level of resistance to various aminoglycosides have been increasingly reported \[[@CR7]\]. To date, 10 types of 16S rRNA methylases, including ArmA, RmtA, RmtB, RmtC, RmtD, RmtE, RmtF, RmtG, RmtH and NpmA, have been found in clinical isolates. Of them, RmtB spread widely among various bacterial species, including *Acinetobacter baumannii*, *Enterobacteriaceae* and *Pseudomonas aeruginosa*, and RmtC spread among *Enterobacteriaceae* \[[@CR7]\].

Methods {#Sec2}
=======

Bacterial strains and antimicrobial susceptibility {#Sec3}
--------------------------------------------------

Twenty-seven *K. pneumoniae* isolates with minimum inhibitory concentrations (MICs) ≥4 mg/L for imipenem or meropenem were obtained from 27 inpatients treated at a hospital, Vietnam, from from February 2014 to April 2015. Of them, 22 isolates were from respiratory tracts, 3 from pus samples, 1 from a bile sample, and 1 from a urine sample. The isolates were phenotypically identified and species identification was confirmed by 16S rRNA sequencing. MICs were determined using the microdilution method, according to the guidelines of the Clinical Laboratory Standards Institute (M100-S25). The colistin MICs were also determined by Etest in colistin-resistant isolates evaluated by broth microdilution method.

Detection of antibiotic-resistance genes and their genetic environments {#Sec4}
-----------------------------------------------------------------------

The entire genome of each isolate was extracted by DNeasy Blood & Tissue kit (QIAGEN, Tokyo, Japan) and sequenced by MiSeq (Illumina, San Diego, CA). Sequences of drug-resistance genes, including β-lactamase encoding genes at the website ([https://www.ncbi.nlm.nih.gov/pathogens/beta-lactamase-data-resources/](https://www.ncbi.nlm.nih.gov/pathogens/beta-lactamase-data-resources)), aminoglycoside resistance genes (aminoglycoside-acetyltransferase, −adenylyltransferase and -phosphotransferase encoding genes), colistin resistance genes (*mcr-1*, *mcr-2* and *mgrB*), registered in GenBank ([http://www.ncbi.nlm.nih.gov/nuccore/](http://www.ncbi.nlm.nih.gov/nuccore)) and quinolone resistance genes *gyrA* and *parC*, were determined using CLC genomics workbench version 9.0.1. Genetic environments surrounding *bla* ~KPC-2~, *bla* ~NDMs~ and *bla* ~OXA-48~ and the genes encoding the 16S rRNA methylases were determined.

MLST and phylogenetic analysis {#Sec5}
------------------------------

Multilocus sequence types (MLSTs) were deduced as described in the protocols of the Institut Pasteur MLST (IP-MLST) (<http://bigsdb.pasteur.fr/klebsiella/klebsiella.html>) databases. Clonal complexes (CC) were determined by eBURST version 3 (<http://eburst.mlst.net>). Single nucleotide polymorphisms (SNPs) of the genome sequences of all carbapenem-resistant isolates tested were identified by comparisons with the sequence of NDM-1 producing ST15 *K. pneumoniae* PMK1, (Gen Bank accession no. CP008929), with all the reads of each isolate aligned against the PMK1 sequence using CLC Genomic Workbench version 9.0.1. SNP concatenated sequences were aligned using MAFFT ([http:/mafft.cbrc.jp/alignment/server/](http://www.mafft.cbrc.jp/alignment/server/)). Phylogenetic trees were constructed from the SNP concatemers. Models and parameters used for the phylogenetic analyses were computed using j-Model Test-2.1.4. A maximum-likelihood phylogenetic tree was constructed from SNP alignment with PhyML 3.0.

Pulsed-field gel electrophoresis and southern hybridization {#Sec6}
-----------------------------------------------------------

The plasmids in each ST strain were extracted and pulsed-field gel electrophoresis was performed as describing previously \[[@CR8]\]. Probes for *bla* ~KPC-2~, *bla* ~NDMs~ and *bla* ~OXA-48~ were amplified by PCR using the primer sets as follows; KPC-F-TCGCTAAACTCGAACAGG and KPC-R-TTACTGCCCGTTGACGCCCAATCC for *bla* ~KPC-2~, NDM-F- TTGGCCTTGCTGTCCTTG and NDM-R- ACACCAGTGACAATATCACCG for *bla* ~NDMs~ and OXA-48-F-TGTTTTTGGTGGCATCGAT and OXA-48-R-GTAAMRATGCTTGGTTCGC for *bla* ~OXA-48~, respectively. Signal detection was carried out using DIG High Prime DNA Labeling and Detection Starter Kit II (Roche Applied Science, Indianapolis, IN).

Nucleotide sequence accession numbers {#Sec7}
-------------------------------------

The whole genome sequences of all 27 isolates have been deposited at GenBank as accession numbers DRA005275.

Results {#Sec8}
=======

Antimicrobial susceptibility {#Sec9}
----------------------------

MICs of 27 carbapenem-resistant isolates were shown in Table [1](#Tab1){ref-type="table"}. All the isolates had MIC~50~ 8 mg/L and MIC~90~ 64 mg/L for imipenem, and MIC~50~ 8 mg/L and MIC~90~ 128 mg/L for meropenem. They were resistant to ampicillin with MICs ≥1024 mg/L, to aztreonam with MIC~50~ 512 mg/L and MIC~90~ 1024 mg/L, to ceftazidime with MIC~50~ 256 mg/L and MIC~90~ \> 1024 mg/L, and to ciprofloxacin with MIC~50~ 256 mg/L and MIC~90~ 512 mg/L. Of all the isolates, 19 isolates (70%) were resistant to amikacin with MIC~50~ 1024 mg/L and MIC~90~ \> 1024 mg/L. They had MIC~50~ 256 mg/L and MIC~90~ \> 1024 mg/L for arbekacin, MIC~50~ 0.25 mg/L and MIC~90~ 32 mg/L to colistin, and MIC~50~ 2 mg/L and MIC~90~ 2 mg/L to tigecycline. The colistin MICs of *K. pneumoniae* isolates were significantly higher by the microdilution method than by Etest. MICs of colistin using Etest were from 0.75 to 2 mg/L (Table [1](#Tab1){ref-type="table"}).Table 1Summary of the characteristics of the 27 *Klebsiella pneumoniae* strains, including antimicrobial resistance profiles, resistance genes and MLSTStrainMIC(mg/L)CarbapenemasesSize of the plasmids harboring carbapenemase encoding genesESBL16S rRNA methylasesAminoglycoside modification enzymesMutations in DNA gyraseMLSTABKAMKAMPAZTCAZCIPCST^a^IPMMEMTGC*gyrAparC*VNC Kp051024\>1024\>10245122562564 (2)881OXA-4850 kbpCTX-M-15, SHV-28, TEM-1RmtBAAC(6′)-Ib-cr, APH(3′)-IaS83Y, D87AS80I15VNC Kp10256512\>1024102451251232 (2)1642OXA-48NDCTX-M-15, SHV-28, TEM-1RmtB-S83Y, D87AS80I15VNC Kp132561024\>102451225625632 (2)882OXA-48NDCTX-M-15, SHV-28, TEM-1RmtBAAC(6′)-Ib-cr, APH(3′)-IaS83Y, D87AS80I15VNC Kp161024\>1024\>102451225651232 (2)842OXA-4850 kbpCTX-M-15, SHV-28, TEM-1RmtBAAC(6′)-Ib-cr, APH(3′)-IaS83Y, D87AS80I15VNC Kp17512\>1024\>10245121282564 (2)884OXA-48NDCTX-M-15, SHV-28, TEM-1RmtBAAC(6′)-Ib-cr, APH(3′)-IaS83Y, D87AS80I15VNC Kp20512\>1024\>10242561282560.25282OXA-48NDCTX-M-15, SHV-28, TEM-1RmtBAAC(6′)-Ib-cr, APH(3′)-IaS83Y, D87AS80I15VNC Kp212561024\>10245121282560.25242OXA-48NDCTX-M-15, SHV-28, TEM-1RmtBAAC(6′)-Ib-cr, APH(3′)-IaS83Y, D87AS80I15VNC Kp2210241024\>102451225625616 (2)16162OXA-48NDCTX-M-15, SHV-28, TEM-1RmtBAAC(6′)-Ib-cr, APH(3′)-IaS83Y, D87AS80I15VNC Kp25256\>1024\>10242562562560.125822OXA-48NDCTX-M-15, SHV-28, TEM-1RmtBAAC(6′)-Ib-cr, APH(3′)-IaS83Y, D87AS80I15VNC Kp285121024\>10245122562568 (0.75)882OXA-48NDCTX-M-15, SHV-28, TEM-1RmtBAAC(6′)-Ib-cr, APH(3′)-IaS83Y, D87AS80I15VNC Kp2914\>102451232320.125441KPC-2150 kbpCTX-M-15, TEM-1, SHV-28-AAC(6′)-Ib-crS83IS80I307VNC Kp3012\>10245121281280.25442OXA-48NDCTX-M-15, SHV-28, TEM-1-AAC(6′)-Ib-cr, AADA16 APH(3′)-IaS83Y, D87AS80I15VNC Kp325121024\>102410242562568 (1)1682OXA-48NDCTX-M-15, SHV-28, TEM-1RmtBAAC(6′)-Ib-cr, APH(3′)-IaS83Y, D87AS80I15VNC Kp342561024\>102451225625632 (2)881OXA-48NDCTX-M-15, SHV-28, TEM-1RmtBAAC(6′)-Ib-cr, APH(3′)-IaS83Y, D87AS80I15VNC Kp35256128\>1024512102425616 (1)882OXA-48NDCTX-M-14, SHV-12, TEM-1RmtBAAC(6′)-Ib-cr, AADA1, APH(3′)-IaS83Y, D87AS80I15VNC Kp39\>1024\>1024\>102432\>10242560.5881NDM-1100 kbpCTX-M-27, SHV-28RmtCAAC(6′)-Ib-cr, AADA16S83IS80I395VNC Kp421616\>1024256\>10246432 (1)32641NDM-4120 kbpCTX-M-15, SHV-28, TEM-1-AAC(6′)-Ib-cr, AADA1, AADA16S83F, D87AS80I15VNC Kp4310241024\>10245122562560.25442OXA-48NDCTX-M-14, SHV-12, TEM-1RmtBAAC(6′)-Ib-cr, AADA1S83Y, D87AS80I15VNC Kp511616\>10241024256640.251641OXA-48NDCTX-M-14, SHV-12, TEM-1-AAC(6′)-Ib-cr, AADA1S83Y, D87AS80I15VNC Kp54\>1024\>1024\>10241024256640.58161OXA-48145.5 kbpCTX-M-14, CTX-M-15, SHV-1, TEM-1RmtBAADA2, APH(3′)-IaS83F, D87NE84K16VNC Kp56\>1024\>1024\>1024512256640.2516161OXA-48NDCTX-M-14, CTX-M-15, SHV-1, TEM-1RmtBAADA2, APH(3′)-IaS83F, D87NE84K16VNC Kp57\>1024\>1024\>102464\>10242560.25641280.5NDM-440 kbpCTX-M-27, SHV-11, TEM-1RmtB-S83IS80I2353VNC Kp6824\>1024512256640.125482OXA-4850 kbpSHV-1, TEM-1-AAC(6′)-Ib-crS83IS80I147VNC Kp701616\>10241024\>10242560.1251282562NDM-4120 kbpCTX-M-14, CTX-M-15, SHV-1, TEM-1-AAC(6′)-Ib-cr, AADA1, AADA2S83F, D87NE84K16VNC Kp72168\>1024128\>10241280.12532642NDM-4NDCTX-M-15, SHV-28, TEM-1-AAC(6′)-Ib-cr, AADA1, AADA16S83F, D87AS80I15VNC Kp731616\>10241024\>10245120.1251282562NDM-4NDCTX-M-14, CTX-M-15, SHV-1, TEM-1-AAC(6′)-Ib-cr, AADA1, AADA2S83F, D87NE84K16VNC Kp77\>1024\>1024\>1024128\>10242560.2516641NDM-1NDCTX-M-27, SHV-28RmtCAAC(6′)-Ib-cr, AADA16S83IS80I395*MIC*, minimum inhibitory concentration, *ABK* arbekacin, *AMK* amikacin, *AMP* ampicillin, *AZT* azidothymidine, *CAZ* ceftazidime, *CIP* ciprofloxacin, *CST* colistin, *IPM* imipenem, *MEM* meropenem, *TGC* tigecycline, *ESBL* extended-spectrum-lactamase, *ND* not determined^a^MICs for colistin using Etest are given in parentheses

Drug resistant genes {#Sec10}
--------------------

All isolates tested had a carbapenemase encoding gene, such as *bla* ~KPC-2~, *bla* ~NDM-1~, *bla* ~NDM-4~ and *bla* ~OXA-48~; and the majority had a 16S rRNA methylase encoding gene, such as *rmtB* and *rmtC* (Table [1](#Tab1){ref-type="table"}). Of the all isolates, 19 had *bla* ~OXA-48~, 5 had *bla* ~NDM-4~, 2 had *bla* ~NDM-1~, and 1 had *bla* ~KPC-2~. Seventeen had *rmtB* and 2 had *rmtC*. These isolates also had (an) extended spectrum β-lactamase encoding gene(s), including *bla* ~CTX-M-14~, *bla* ~CTX-M-15~, *bla* ~CTX-M-27~, *bla* ~SHV-1~, *bla* ~SHV-11~, *bla* ~SHV-12~, *bla* ~SHV-28~, *bla* ~SHV-55~, and/or *bla* ~TEM-1~; and aminoglycoside modification enzymes, including *aac(6′)-Ib-cr* and/or *aadA1* (Table [1](#Tab1){ref-type="table"}). All isolates had 2 or 3 point mutations in the quinolone-resistance-determining regions of *gyrA* and *parC* (Table [1](#Tab1){ref-type="table"}). None of the isolates harbor *mcr-1* or *mcr-2*, and our analysis did not reveal any isolates with disruption in the *mrgB* gene.

Genetic environments surrounding genes encoding carbapenemases {#Sec11}
--------------------------------------------------------------

The genetic structure surrounding *bla* ~KPC-2~, *bla* ~NDM-1~, *bla* ~NDM-4~ and *bla* ~OXA-48~ were shown in Fig. [1](#Fig1){ref-type="fig"}. The genomic structure surrounding *bla* ~KPC-2~ was identical with that of *Aeromonas hydrophila* strain WCHAH01 plasmid pKPC2 (GenBank accession no. KR014106), which was isolated in China.Fig. 1The structure of genetic environments surrounding *bla* ~KPC-2~, *bla* ~NDM-1~, *bla* ~NDM-4~ and *bla* ~OXA-48~

All isolates harboring *bla* ~NDM-1~ tested had the same genetic structure surrounding *bla* ~NDM-1~ (Fig. [1](#Fig1){ref-type="fig"}), which was identical with that of plasmid pRIH26 in NDM-1 producing *K. pneumoniae* isolated from a patient in 2012 in Rhode Island, the United States \[[@CR9]\]. This patient had returned to the United States after a hospitalization in Vietnam \[[@CR9]\].

All isolates harboring *bla* ~NDM-4~ tested had the same genetic structure surrounding *bla* ~NDM-4~ (Fig. [1](#Fig1){ref-type="fig"}), which was identical to that of NDM-1 producing *K. pneumoniae* strain KP4 plasmid pKP04NDM isolated in China (GenBank accession no. KU314941).

OXA-48 producers had either one of two genetic structures surrounding *bla* ~OXA-48~ (Fig. [1](#Fig1){ref-type="fig"}). Of them, one was not reported (the second structure from the bottom in Fig. [1](#Fig1){ref-type="fig"}), whereas the other was identical with plasmids in OXA-48 producing *K. pneumoniae* strains 153,877--1 in Netherlands (GenBank accession no. KP659188), KP112 in France (GenBank accession no. LN864819), Kpn-E1.Nr7 in Switzerland (GenBank accession no. KM406491), E71T in Ireland (GenBank accession no. KC335143), KP1 and KP2 in France (GenBank accession no. KC757416 and KC757417, respectively), and 23 plasmid pIncL_M\_DHQP1400954 in the USA (GenBank accession no CP016927).

The *bla* ~KPC-2~, *bla* ~NDM-1~, *bla* ~NDM-4~ and *bla* ~OXA-48~ in each ST strain will be all located on plasmids and the sizes of the plasmids were shown in Table [1](#Tab1){ref-type="table"}.

MLST and molecular phylogenetic analysis {#Sec12}
----------------------------------------

The clinical isolates of *K. pneumoniae* tested belonged to either one of ST15, ST16, ST147, ST307, ST395 and ST2353 (Table [1](#Tab1){ref-type="table"}). Of these isolates, 18 belonged to ST15 and 4 belonged to ST16 (Table [1](#Tab1){ref-type="table"}). The new sequence type, ST2353, belonged to CC147. Phylogenetic analysis revealed that the isolates belonging to ST15 formed the largest clade among the 27 isolates (Fig. [2a](#Fig2){ref-type="fig"}). The 18 isolates belonging to ST15 harbored either one of two genes encoding carbapenemases, including *bla* ~OXA-48~ and *bla* ~NDM-4~; and genes encoding aminoglycoside resistance factors, including *aac(6′)-Ib-cr* and *rmtB* (Table [1](#Tab1){ref-type="table"}). The phylogenetic tree among 18 ST15 isolates showed two subclades, A and B (Fig. [1b](#Fig1){ref-type="fig"}). Of them, 16 belonging to subclade A harbored *bla* ~OXA-48~ and 2 belonging to subclade B harbored *bla* ~NDM-4~ (Fig. [2b](#Fig2){ref-type="fig"}).Fig. 2**a** Molecular phylogeny of the 27 *K. pneumoniae* strains*.* A maximum-likelihood phylogenetic tree was constructed from the 27 carbapenem-resistant isolates. The isolates belonging to ST15 formed the largest clade among the 27 isolates. **b** Molecular phylogeny of the 18 *K. pneumoniae* strains belonging to ST15*.* A maximum-likelihood phylogenetic tree was constructed from the 18 carbapenem-resistant isolates. Of them, 16 belonging to subclade A harbored *bla* ~OXA-48~ and 2 belonging to subclade B harbored *bla* ~NDM-4~

Discussion {#Sec13}
==========

To our knowledge, this is the first report of the whole genome based molecular epidemiological analysis of carbapenem-resistant *K. pneumoniae* in Vietnam. Our study suggests that carbapenem-producing ST15 *K. pneumoniae* have been spreading in medical settings in Vietnam. A NDM-1 producing *K. pneumoniae* clinical isolate in Vietnam was firstly obtained from a urinary tract of a 62-year-old man in 2010 \[[@CR10]\].

This is the first report of NDM-4 or OXA-48 producing *K. pneumoniae* in Vietnam. NDM-4 was firstly detected in *E. coli* I5, which was recovered from a urine sample of a patient hospitalized in 2010 in India \[[@CR11]\]. Since then, NDM-4 producers were reported in *Enterobacter cloacae* in Sri Lanka \[[@CR12]\], *E. coli* in India \[[@CR13]\], Italy \[[@CR14]\] and Vietnam \[[@CR15]\], and *K. pneumoniae* in Japan \[[@CR16]\]. NDM-4 possessed increased hydrolytic activity toward carbapenems and several cephalosporins compared to NDM-1 \[[@CR11]\]. NDM-4 with an amino acid substitution at position 130 (Met to Leu) showed increased hydrolytic activity toward carbapenems and several cephalosporins compared to NDM-1 \[[@CR11]\].

ST15 will be an emerging high-risk multidrug-resistant clone with carbapenem-encoding genes, including *bla* ~KPCs~, *bla* ~NDMs~ and *bla* ~OXAs~. Outbreaks caused by ST15 OXA-48 produces were reported in France and Spain \[[@CR2]\]. When Diancourt et al. \[[@CR17]\] developed a MLST for *K. pneumoniae* in 2005, they already detected ST15 isolates from several countries in Europe, such as Austria, France, Portugal and Poland, and the most of the isolates were resistant to ceftazidime and ciprofloxacin. ST15 *K. pneumoniae* isolates were reported to spread in medical settings in 2005 in Hungary \[[@CR2]\]. ST15 *K. pneumoniae* isolates were detected in other European countries, including Bulgaria, Croatia, Czech Republic, Denmark, Hungary, Italy, Netherlands, and Spain \[[@CR2]\]; they were also detected in Asian countries, including China, South Korea, Malaysia, Singapore, Thailand, and Vietnam \[[@CR2]\]; in African countries, including Côte d'Ivoire, Madagascar, Morocco, and Senegal \[[@CR18]\]. These ST15 isolates frequently produced ESBL, including CTX-M, SHV-28 and TEM variants \[[@CR19]\], and moreover, they became to produce various carbapenemases, including KPCs, OXA-48, NDMs and VIM-4 \[[@CR19]\]. One of the well-recognized high-risk clones is CC258 which is frequently associated with KPCs-producing *K. pneumoniae* known as a high-risk clone \[[@CR19]\], and these isolates were reported many countries, such as the United States, Greek, Norway, Sweden, Italy, Poland, Canada, Brazil and Korea \[[@CR19]\]. ST11, a related clone ST258, was reported in KPCs-producing isolates mainly in China, but also in NDMs-producers from Czech Republic, Switzerland, Thailand, Australia, the United States, the United Arab Emirates and Greece \[[@CR19]\].

Etest seems a more reliable method to measure colistin MICs than broth microdilution method \[[@CR20], [@CR21]\]. In the present study, 11 isolates were resistant to colistin with MICs 4--32 mg/L by broth microdilution method, although none of the isolates had colistin-resistant factors. Our previous study indicated that *Enterobacteriacae* isolates showed lower colistin MICs by Etest than by broth microdilution method \[[@CR20]\]. It is necessary to find feasible susceptibility testing methods of determining the MICs of polymyxins for clinical laboratories.

Conclusions {#Sec14}
===========

This study showed that carbapenem-resistant *K. pneumoniae* isolates belonged to international clones spread, and that these isolates harbored genes encoding various combinations of carbapenemases and 16S rRNA methylases, in a medical setting in Vietnam.

ESBLs

:   extended-spectrum β-lactamases

MBLs

:   Metallo-β-lactamases

MICs

:   minimal inhibition concentration

MLST

:   Multilocus sequence typing

Biosafety Committee of the National Center for Global Health and Medicine (approval number: 27-M-52).

Funding {#FPar1}
=======

This study was supported by Japan Initiative for Global Research Network on Infectious Diseases (J-GRID), and a grant of the Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and Development (AMED), a grant (27-A-1102) from International Health Cooperation Research, and JSPS KAKENHI Grant Number 16 K19133.

Availability of data and materials {#FPar2}
==================================

Nucleotide sequence accession numbers of the whole genome sequences of all 27 isolates have been deposited at GenBank as accession numbers DRA005275.

TT and MT: Performed whole genome sequencing, analyzed data and drafted the manuscript. KS: Performed drug-susceptibility tests. TTTN: Performed clinical bacterial analyses. LTAT and TTP: Designed protocols and supervised this study at CRH. NO and TK: Designed protocols and supervised this study. All authors read and approved the final manuscript.

Ethical approval and consent to participate {#FPar3}
===========================================

The study protocol was carefully reviewed and approved by the ethics committee of Cho Ray Hospital (approval number: 1644/QD-BVCR), the ethics committee of the National Center for Global Health and Medicine (No. 1268), respectively. Respectively. Individual informed consent was waived by the ethics committee listed above because this study used currently existing sample collected during the course of routine medical care and did not pose any additional risks to the patients.

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interest.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
